The A.A.O. recommends that adults with no signs or risk factors for eye disease get a comprehensive exam at 40 to establish a ...
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that a $15 million milestone payment due Tarsus has been achieved following regulatory approval of TP-03 (lotilaner ophthalmic solution) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results